Mannkind, Game-Chancer in Sachen Diabetik? (Seite 92)

[price-of-success]

Jedoch dies von stocktwits zum gestrigen update durch Mike
Combined Positives Part 1

💥 Pediatric Clinical Trial
💥 Dexcom Clinical Trial
💥 United Therapeutics / MannKind Treprostinil Technosphere Clinical Trial
💥 India Clinical Trial
💥 BluHale Pro Launch
💥 Australia Regulatory Filing Approval
💥 FDA Approval on Advanced Expiration Dating
💥 United Therapeutics Second Molecule
💥 United Therapeutics Milestone Payments
💥 Pipeline Partnership(s)
💥 Pipeline Expansion
💥 Further Debt Reduction
💥 Increased International Expansion
💥 Brazil Afrezza Sales
💥 Receptor Life Sciences
💥 COVID-19 Pipe Program with Immix
💥 Continued Expansion of Vdex Clinics around the country = increased scripts, increased sales, increased cash Bullish

[pegasusorion]

Hat jemand schon die neuen Zahlen zu den Wochenumsätzen?

Vielen Dank vorab :-)

[pegasusorion]

In den USA gabs doch das Problem mit den plötzlich vielen Toten durch Inhalation von E-Zigaretten.

Ich denke das könnte 1 ner der Gründe sein, Sippenhaft?? wobei Inhalation deutlich besser ist als Spritzen---alleine schon das nicht vorhandene Infektion s Risiko durch die fehlende Nadel.

[price-of-success]

Sehr gute Frage . Warum bloss nicht?
Ich würde stets inhalieren . Spritzen könnte ich niemals

[lobberland]

Antwort auf Beitrag Nr.: 63.694.660 von questionmark am 15.05.20 14:33:20

Darin sehe ich das Problem
Warum bleiben die nicht 🤔

[questionmark]

Antwort auf Beitrag Nr.: 63.694.438 von price-of-success am 15.05.20 14:21:36

nicht nur dass die neuen Verschribungen nicht mehr werden, die "Kunden" bleiben auch nicht lange, wie es scheint, da die refills auch nicht signifikant zunehmen.
Schon komisch, dass da wenig geht ...

[price-of-success]

Trx 721. kleine Steigerung zur Vorwoche from stocktwits

[Magnetfeldfredy]

Die Scripts sind nicht gut aber beim CoronaKnock Down kannst Du nicht mehr erwarten, die Zahlen werden zurückkommen.
Viel wichtiger ist nach lesen des CC-transcripts, dass mit TreT-Programm der real-game changer bevorsteht, 400 Millionen-1 Milliarde Umsatz bei UTHR und Mannkind erhält nach Zuzlassung mindestens 10 % revenues, das wären 40-100 Millionen pro Jahr und damit Mannkind aller Sorgen los!
Das wird innerhalb von 12-15 Monaten kommen und der Kurs bei US Dollar 5 stehen:

Michael E. Castagna, MannKind Corporation - CEO & Director [32]

--------------------------------------------------------------------------------

Yes, Bert. Look, when we entered a deal with United, we knew that trial was coming. Obviously it was early. Wouldn't know the readout was. And having a positive readout, I think it was in WHO III criteria, literally expanded the market dramatically for Tyvaso. And we would expect our TreT program to be able to participate in that market expansion. In fact, it'll probably help penetrate that market because of the easier delivery platform that we have and the administration time and backup supplies you need, et cetera. So, we're very excited. We went into this expecting Tyvaso and PAH, and we felt that alone was a good enough partnership to make this a worthwhile endeavor for both companies. And now this is all upside. And we've got to think through that forecast. We have to think through that as a manufacturing capacity. Think about that in our packaging. So it definitely changes, and we're working closely every week to make sure we continue to supply patients in BREEZE, but also think about the interstitial lung disease indication and how we prepare for that with TreT. So we're very excited about treprostinil. We think that will ride the future capital of the company to ensure continued acceleration of growth as we get out there. And just to remind investors, we will receive double digit royalties upon approval. So this -- Tyvaso today does a little over $400 million. So these are significant when you look out and see where Afrezza revenues will be and Tyvaso on top of it. So, we're excited. Other questions, Bert? You missed our record revenue.

--------------------------------------------------------------------------------

Robert Cummins Hazlett, BTIG, LLC, Research Division - MD & Biotechnology Equity Research Analyst [33]

--------------------------------------------------------------------------------

Sorry. I'm muted. Are you contemplating additional -- are you additional expansion even beyond the TreT patients in your manufacturing plants? Again, they're talking fairly substantial, even about beyond the most recent data. So I'm just kind of curious as to what extent that's being contemplated in MannKind.

--------------------------------------------------------------------------------

Michael E. Castagna, MannKind Corporation - CEO & Director [34]

--------------------------------------------------------------------------------

Yes. We are the CMO for treprostinil DPI, so obviously we're in discussions with them. We'll work accordingly. We have time on our side to scale up where we need to. So we think about a filing within in the next I'll call it 12 months or sooner, plus the FDA review time, that gives you plenty of time to continue to figure out what you need to scale up manufacturing to supply the market. But if I recall, Martine -- maybe it was JPMorgan or investor meeting in the fall, but she sees Tyvaso being a billion dollar product. That gets us very excited as we think about our future. So we always thought this was a great program, a great opportunity to help patients. And I think the patients in the BREEZE study are demonstrating the success of this product as we know there's a rollover phase, and we're seeing what people are doing in the rollover phase and they're staying on the product and they're happy. So I'm excited to help more patients with our technology, and I think it just continues to help demonstrate the platform, what else it can do for other diseases beyond PAH, ILD, diabetes, migraine, et cetera. So Bert, if anything, it just reinforces we got to continue with this pipeline and the company forward and find additional partners to move the company down the road and expand the technology.

--------------------------------------------------------------------------------

[price-of-success]

🤮🙏🙊🙈

[price-of-success]

Trx 649. stocktwits